GLP-1 Receptor Agonists

Cagrilintide and Semaglutide

Records checked

Compiled and citation-checked by GLP-1 Receptor Agonists editorial desk

Qualified clinical review None on record

Withheld from the index. This page sets out the indexed clinical-record picture for Cagrilintide and Semaglutide.

Every compound in scope is marked high impact and none has a qualified clinical reviewer recorded, so this page is built, checked and served with a noindex directive and left out of the sitemap. Nothing on it has been removed or softened. Recording a named reviewer publishes it unchanged on the next build. How the gate works.

Cagrilintide and Semaglutide are curated as a pair under Incretin receptor agonists. This page reads them across four axes at once: what each one is recorded as binding, what the molecule is, what shape its indexed record set has, and what the application register returned. Every cell is either a sourced value or a count of records.

A larger record count is not a better compound. Counts track how long a compound has been studied and how heavily it has been indexed, nothing else. Nothing on this page ranks the two.

Identity and target

AxisCagrilintideSemaglutide
Class as recordedAmylin and amylin receptor agonists, also carried under Incretin receptor agonistsIncretin receptor agonists
Receptor targets as recordedAmylin receptor, Calcitonin receptorGLP-1 receptor
Molecular formulaC194H312N54O59S2[6]C187H291N45O59[14]
Molecular weight4409 g/mol[6]4114 g/mol[14]
CAS registry number1415456-99-3[6]910463-68-2[14]
Reported half-lifeUnknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated.Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated.
Applications on the registerNone on the query date[7]1 on the query date[15]

Shape of the indexed record set

AxisCagrilintideSemaglutide
Records indexed here1212
Phase 3 records63
Phase 2 records01
Phase 1 records00
Trial records with no phase assigned03
Review or synthesis records10
Records that are not registered trials55
Study models as assignedhuman trial 7; other 3; rodent 2human trial 10; other 2
Publication years covered2025–20262024–2025
Derived record-set tierHuman trial evidenceHuman trial evidence
Basis of that tier7 of 12 indexed records are interventional human trials by their own assigned publication type10 of 12 indexed records are interventional human trials by their own assigned publication type
Review statePending qualified reviewPending qualified review

The derived tier counts record types. It is not an assessment of clinical efficacy, of safety, of study quality or of consensus, and the two tiers on this row are not a verdict about which compound is better supported.

Endpoint coverage, side by side

AxisCagrilintideSemaglutide
Body weight and adiposity77
Glycaemic control75
Cardiovascular16
Renal12
Hepatic11
Neurological20

Each endpoint is defined by a fixed set of subject headings, printed in full on the endpoint pages.

Which axes diverge

16 of the 23 axes above differ between the two, 6 carry the same value, and 1 are unsourced on both sides. A divergence is a difference in what the corpus records, not a difference in what either compound does.

ResultAxes
DifferClass as recorded; Receptor targets; Molecular formula; Molecular weight; CAS registry number; Applications on the register; Phase 3 records; Phase 2 records; Unphased trial records; Review records; Study models; Publication years; Glycaemic control records; Cardiovascular records; Renal records; Neurological records
Same valueRecords indexed; Phase 1 records; Non-trial records; Derived record-set tier; Body weight and adiposity records; Hepatic records
Unsourced on both sidesReported half-life

The corpus also carries a curated divergence note for this pair, written for the reference layer rather than for this one. It is not reproduced here; the records behind it are cited[1, 2, 3, 4, 5] and listed in the sources below.

Records indexed under both

No record in this corpus is indexed under both compounds. That is the absence of a retrieved head-to-head record in this selection, not evidence that none exists.

Where this page sits

Sources

  1. Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of medicinal chemistry (2021). pmid:34288673
  2. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet (London, England) (2023). pmid:37364590
  3. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine (2025). pmid:40544433
  4. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med (2021). pmid:33567185
  5. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med (2016). pmid:27633186
  6. PubChem Compound Summary for CID 171397054, Cagrilintide. PubChem, National Library of Medicine (2026). pubchem:171397054
  7. Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:cagrilintide
  8. AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. The Journal of pharmacology and experimental therapeutics (2021). pmid:33727283
  9. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine (2025). pmid:40609154
  10. Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2022). pmid:36242844
  11. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet (London, England) (2021). pmid:34798060
  12. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet (London, England) (2021). pmid:33894838
  13. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. The New England journal of medicine (2025). pmid:40544432
  14. PubChem Compound Summary for CID 56843331, Semaglutide. PubChem, National Library of Medicine (2026). pubchem:56843331
  15. Drugs@FDA application register query for this compound, 1 application(s) returned: NDA213051. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:semaglutide
  16. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med (2023). pmid:37952131
  17. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med (2021). pmid:33185364
  18. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med (2024). pmid:38785209
  19. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med (2021). pmid:34170647
  20. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther (2024). pmid:39289339
  21. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ (2024). pmid:38286487